Jason L Sanders1, Wensheng Guo2, Ellen S O'Meara3, Robert C Kaplan4, Michael N Pollak5, Traci M Bartz6, Anne B Newman7, Linda P Fried8, Anne R Cappola9. 1. Department of Medicine, Massachusetts General Hospital, Boston. 2. Division of Biostatistics, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia. 3. Kaiser Permanente Washington Health Research Institute, Seattle. 4. Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York. 5. Cancer Prevention Research Unit, Departments of Medicine and Oncology, Lady Davis Research Institute of Jewish General Hospital and McGill University, Montreal, Quebec, Canada. 6. Department of Biostatistics, University of Washington, Seattle. 7. Department of Epidemiology, University of Pittsburgh, Pennsylvania. 8. Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York. 9. Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia.
Abstract
Background: Disruption of insulin-like growth factor-I (IGF-I) increases health and life span in animal models, though this is unconfirmed in humans. If IGF-I stability indicates homeostasis, the absolute level of IGF-I may be less clinically relevant than maintaining an IGF-I setpoint. Methods: Participants were 945 U.S. community-dwelling individuals aged ≥65 years enrolled in the Cardiovascular Health Study with IGF-I levels at 3-6 timepoints. We examined the association of baseline IGF-I level, trajectory slope, and variability around the trajectory with mortality. Results: There were 633 deaths over median 11.3 years of follow-up. Lower IGF-I levels, declining or increasing slope, and increasing variability were each individually associated with higher mortality (all p < .001). In an adjusted model including all three trajectory parameters, baseline IGF-I levels <70 ng/mL (hazard ratio [HR] 1.58, 95% CI 1.28-1.96 relative to IGF-I levels of 170 ng/mL), steep declines and steep increases in trajectory slope (HR 2.22, 1.30-3.80 for a 15% decline; HR 1.40, 1.07-1.84 for a 10% decline; HR 1.80, 1.12-2.89 for a 15% increase; HR 1.31, 1.00-1.72 for a 10% increase, each vs no change), and variability ≥10% (HR 1.59, 1.09-2.32 for ≥ 30%; HR 1.36, 1.06-1.75 for 20%; and HR 1.17, 1.03-1.32 for 10% variability, each vs 0%) in IGF-I levels were independently associated with mortality. Conclusions: In contrast to data from animal models, low IGF-I levels are associated with higher mortality in older humans. Irrespective of the actual IGF-I level, older individuals with stability of IGF-I levels have lower mortality than those whose IGF-I levels fluctuate over time.
Background: Disruption of insulin-like growth factor-I (IGF-I) increases health and life span in animal models, though this is unconfirmed in humans. If IGF-I stability indicates homeostasis, the absolute level of IGF-I may be less clinically relevant than maintaining an IGF-I setpoint. Methods:Participants were 945 U.S. community-dwelling individuals aged ≥65 years enrolled in the Cardiovascular Health Study with IGF-I levels at 3-6 timepoints. We examined the association of baseline IGF-I level, trajectory slope, and variability around the trajectory with mortality. Results: There were 633 deaths over median 11.3 years of follow-up. Lower IGF-I levels, declining or increasing slope, and increasing variability were each individually associated with higher mortality (all p < .001). In an adjusted model including all three trajectory parameters, baseline IGF-I levels <70 ng/mL (hazard ratio [HR] 1.58, 95% CI 1.28-1.96 relative to IGF-I levels of 170 ng/mL), steep declines and steep increases in trajectory slope (HR 2.22, 1.30-3.80 for a 15% decline; HR 1.40, 1.07-1.84 for a 10% decline; HR 1.80, 1.12-2.89 for a 15% increase; HR 1.31, 1.00-1.72 for a 10% increase, each vs no change), and variability ≥10% (HR 1.59, 1.09-2.32 for ≥ 30%; HR 1.36, 1.06-1.75 for 20%; and HR 1.17, 1.03-1.32 for 10% variability, each vs 0%) in IGF-I levels were independently associated with mortality. Conclusions: In contrast to data from animal models, low IGF-I levels are associated with higher mortality in older humans. Irrespective of the actual IGF-I level, older individuals with stability of IGF-I levels have lower mortality than those whose IGF-I levels fluctuate over time.
Authors: Hau Liu; Dena M Bravata; Ingram Olkin; Smita Nayak; Brian Roberts; Alan M Garber; Andrew R Hoffman Journal: Ann Intern Med Date: 2007-01-16 Impact factor: 25.391
Authors: K G O'Connor; J D Tobin; S M Harman; C C Plato; T A Roy; S S Sherman; M R Blackman Journal: J Gerontol A Biol Sci Med Sci Date: 1998-05 Impact factor: 6.053
Authors: William E Sonntag; Anna Csiszar; Raphael deCabo; Luigi Ferrucci; Zoltan Ungvari Journal: J Gerontol A Biol Sci Med Sci Date: 2012-04-20 Impact factor: 6.053
Authors: Ronenn Roubenoff; Helen Parise; Hélène A Payette; Leslie W Abad; Ralph D'Agostino; Paul F Jacques; Peter W F Wilson; Charles A Dinarello; Tamara B Harris Journal: Am J Med Date: 2003-10-15 Impact factor: 4.965
Authors: S Boonen; R Lysens; G Verbeke; E Joosten; E Dejaeger; W Pelemans; J Flamaing; R Bouillon Journal: Age Ageing Date: 1998-07 Impact factor: 10.668
Authors: Valter D Longo; Adam Antebi; Andrzej Bartke; Nir Barzilai; Holly M Brown-Borg; Calogero Caruso; Tyler J Curiel; Rafael de Cabo; Claudio Franceschi; David Gems; Donald K Ingram; Thomas E Johnson; Brian K Kennedy; Cynthia Kenyon; Samuel Klein; John J Kopchick; Guenter Lepperdinger; Frank Madeo; Mario G Mirisola; James R Mitchell; Giuseppe Passarino; Karl L Rudolph; John M Sedivy; Gerald S Shadel; David A Sinclair; Stephen R Spindler; Yousin Suh; Jan Vijg; Manlio Vinciguerra; Luigi Fontana Journal: Aging Cell Date: 2015-04-22 Impact factor: 9.304
Authors: Annewieke W van den Beld; Olga D Carlson; Maire E Doyle; Dimitris Rizopoulos; Luigi Ferrucci; Aart Jan van der Lely; Josephine M Egan Journal: Eur J Endocrinol Date: 2019-02-01 Impact factor: 6.664
Authors: Jason L Sanders; Alice M Arnold; Robert M Boudreau; Calvin H Hirsch; Jorge R Kizer; Robert C Kaplan; Anne R Cappola; Mary Cushman; Mini E Jacob; Stephen B Kritchevsky; Anne B Newman Journal: J Gerontol A Biol Sci Med Sci Date: 2019-01-01 Impact factor: 6.053
Authors: Tamas Kiss; Ádám Nyúl-Tóth; Rafal Gulej; Stefano Tarantini; Tamas Csipo; Derek M Huffman; Anna Csiszar; Zoltan Ungvari; Peter Mukli; Anna Ungvari; Priya Balasubramanian; Andriy Yabluchanskiy; Zoltan Benyo; Shannon M Conley; Jonathan D Wren; Lori Garman Journal: Geroscience Date: 2022-02-05 Impact factor: 7.581
Authors: Luke A Hoekstra; Tonia S Schwartz; Amanda M Sparkman; David A W Miller; Anne M Bronikowski Journal: Funct Ecol Date: 2019-09-09 Impact factor: 5.608
Authors: Stefano Tarantini; Ádám Nyúl-Tóth; Andriy Yabluchanskiy; Tamas Csipo; Peter Mukli; Priya Balasubramanian; Anna Ungvari; Peter Toth; Zoltan Benyo; William E Sonntag; Zoltan Ungvari; Anna Csiszar Journal: Geroscience Date: 2021-08-12 Impact factor: 7.713
Authors: David Stevens; Deirdre A Lane; Stephanie L Harrison; Gregory Y H Lip; Ruwanthi Kolamunnage-Dona Journal: BMC Med Res Methodol Date: 2021-12-18 Impact factor: 4.615